American Association for Cancer Research
10780432ccr151984-sup-154228_3_supp_3485435_q6x1lr.docx (15.62 kB)

Supplementary Table S1 from High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer

Download (15.62 kB)
journal contribution
posted on 2023-03-31, 18:21 authored by Carla L. Alves, Daniel Elias, Maria Lyng, Martin Bak, Tove Kirkegaard, Anne E. Lykkesfeldt, Henrik J. Ditzel

Alteration in gene expression of the cyclin D/CDK4-6/p16INK4a/Rb pathway in endocrine-resistant cell line models as determined by gene array.


Danish Cancer Society

Danish Research Council

Danish Cancer Research Foundation

A Race Against Breast Cancer

Sino-Danish Breast Cancer Research Centre

NanoCAN Lundbeck Center of Excellence

Region of Southern Denmark Research Foundation

Odense University Hospital Research Council

AgeCare OUH Elite Center

Danish Center for Translational Breast Cancer Research



Purpose: Resistance to endocrine therapy in estrogen receptor–positive (ER+) breast cancer remains a major clinical problem. Recently, the CDK4/6 inhibitor palbociclib combined with letrozole or fulvestrant was approved for treatment of ER+ advanced breast cancer. However, the role of CDK4/6 in endocrine resistance and their potential as predictive biomarkers of endocrine treatment response remains undefined.Experimental Design: We investigated the specific role of increased CDK6 expression in fulvestrant-resistant cells by gene knockdown and treatment with palbociclib, and evaluated the effect in cell proliferation, apoptosis, and kinase activity. Furthermore, we evaluated CDK6 expression in metastatic samples from breast cancer patients treated or not with fulvestrant.Results: We found increased expression of CDK6 in two fulvestrant-resistant cell models versus sensitive cells. Reduction of CDK6 expression impaired fulvestrant-resistant cell growth and induced apoptosis. Treatment with palbociclib resensitized fulvestrant-resistant cells to fulvestrant through alteration of retinoblastoma protein phosphorylation. High CDK6 levels in metastatic samples from two independent cohorts of breast cancer patients treated with fulvestrant (N = 45 and 46) correlated significantly with shorter progression-free survival (PFS) on fulvestrant treatment (P = 0.0006 and 0.018), whereas no association was observed in patients receiving other first- or second-/third-line endocrine treatments (N = 68, P = 0.135 and 0.511, respectively).Conclusions: Our results indicate that upregulation of CDK6 may be an important mechanism in overcoming fulvestrant-mediated growth inhibition in breast cancer cells. Patients with advanced ER+ breast cancer exhibiting high CDK6 expression in the metastatic lesions show shorter PFS upon fulvestrant treatment and thus may benefit from the addition of CDK4/6 inhibitors in their therapeutic regimens. Clin Cancer Res; 22(22); 5514–26. ©2016 AACR.

Usage metrics

    Clinical Cancer Research